LYSARC conducts phase I (including first-in-man), II, III (including international, pivotal, registration studies) and IV clinical trials, exclusively in the field of lymphoma. These trials may comprise an industrial objective or have an academic purpose only.
It also has the ability to implement a long-term post-protocol follow-up (survival, late toxicities) of patients in these studies.
From its databases, LYSARC can perform retrospective studies: clinical-biological correlations, subpopulation studies and meta-analyzes.
Finally, LYSARC also contributes to ancillary projects in biology, histopathology or imaging from studies conducted by LYSA.